Skip to main content

Cell Death at the interface of host-intracellular bacterial pathogens

RYC2019-027799-I

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprogram Subprograma Estatal de Incorporación
Call Ramón y Cajal
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSIDAD DE MURCIA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Tesis de maestría (MasterThesis)

Disección del papel de progranulina en tuberculosis, Dissection of the role of progranulin in tuberculosis, Dissecció del paper de progranulina en tuberculosi

  • Moreno García, Elsa María
[ES] La progranulina (PGRN) es una citoquina perteneciente a la familia del factor de necrosis tumoral (TNF) α, la cual es principalmente secretada, y tiene actividad pleiotrópica. Desempeña un papel como factor de crecimiento durante la reparación tisular, el desarrollo embrionario y la diferenciación celular, además de ser un regulador de la respuesta inmunitaria. PGRN es el precursor de diferentes péptidos de 6 kDa llamados granulinas, que se generan mediante un procesamiento proteolítico. Tanto el precursor PGRN como sus formas maduras, las granulinas, son biológicamente activas. La producción de granulinas está estrechamente regulada mediante la interacción directa de PGRN con proteínas inhibidoras del procesamiento y la modulación de las proteasas responsables de su proteólisis. El papel de PGRN y las granulinas ha sido principalmente estudiado por su implicación en el cáncer. PGRN promueve la proliferación y supervivencia celular, la angiogénesis, la migración celular, la evasión inmune y puede contribuir al desarrollo de resistencia a los tratamientos. Además, PGRN participa en la respuesta inflamatoria frente a infecciones causadas por virus, bacterias y hongos, así como en enfermedades autoinmunes, desempeñando diferentes papeles o incluso opuestos según el contexto. En general, PGRN exhibe una potente actividad antiinflamatoria, mientras que las granulinas son altamente proinflamatorias. En este proyecto, se estudiará el papel de PGRN y las granulinas como reguladores de la respuesta inflamatoria en el contexto de la tuberculosis, una devastadora enfermedad infecciosa causada por Mycobacterium tuberculosis (Mtb) utilizando como modelo el pez cebra - Mycobacterium marinum. Recientemente, el laboratorio ha demostrado recientemente que la deficiencia de PGRN y sus derivados confiere resistencia a la tuberculosis en peces cebra adultos, lo que sugiere que PGRN es un factor de susceptibilidad para esta enfermedad. Sin embargo, este fenotipo no se ha reproducido en larvas, donde la ausencia de PGRN provoca un defecto en la diferenciación mieloide sin afectar la capacidad del organismo para combatir la infección., [EN] The cytokine progranulin (PGRN) is a member of the tumor necrosis factor (TNF) α family, primarily secreted, with pleiotropic activity. It plays a role as a growth factor during tissue repair, embryonic development, and cell differentiation, and it is a regulator of the immune response. PGRN is the precursor of different 6 kDa peptides called granulins after proteolytic processing with both the precursor PGRN and the mature forms granulins being biologically active. These cytokines are tightly regulated by direct interaction of PGRN with processing-inhibiting proteins and the modulation of proteases responsible for its proteolysis. The role of PGRN and granulins have been studied for their involvement in cancer. PGRN promotes cell proliferation and survival, angiogenesis, cell migration, immune evasion, and may contribute to the development of treatment resistance. PGRN is also involved in the inflammatory response to infections caused by viruses, bacteria, and fungi, as well as in autoimmune diseases, playing different or even opposing roles depending on the context. In general, PGRN exhibits potent anti-inflammatory activity, while granulins are highly pro-inflammatory. Here, this project focuses on the role of PGRN and granulins as regulators of the inflammatory response in the context of tuberculosis, a devastating infectious disease caused by Mycobacterium tuberculosis (Mtb) using zebrafish- Mycobacterium marinum as a model. The laboratory has recently demonstrated that PGRN and its derivative deficiency leads to resistance to tuberculosis, making it a susceptibility factor for this disease. However, in this project, it was observed that this phenotype does not occur in larvae. Additionally, PGRN deficiency in larvae leads to a defect in myeloid differentiation, which does not impact the ability to fight the disease., Este trabajo ha recibido apoyo de ESF Investing in your Future Fellowship (RYC2019-027799-I/AEI/10.13039/501100011033) HR21 2021 “la Caixa” Health Research Projects, area of Infectious Diseases, (LCF/PR/HR21/52410027), y del Ministerio de Ciencia e Innovación (PID2022-139754OB-I00), proyectos adjudicados a Francisco José Roca Soler
IRTA Pubpro. Open Digital Archive
Publication Artículo científico (JournalArticle)

The study of immunological markers in tuberculosis across animal models and its translation to human research

  • Díaz-Fernández, Sergio
  • Aleluia, Matilde
  • Saraiva, Margarida
  • Soldevilla, Pablo
  • Torrelles, Jordi B.
  • Sharan, Riti
  • Verreck, Frank A. W.
  • Izzo, Angelo
  • Vidal, Maria
  • Moreira, Ana C.
  • Pérez de Val, Bernat
  • Roca, Francisco Jose
  • Preda, Madalina
  • Torrents, Eduard
  • Julián, Esther
  • Domínguez, José
  • Latorre, Irene
Tuberculosis (TB), a disease caused by Mycobacterium tuberculosis, remains one of the major causes of death from infection worldwide, with over a million associated deaths each year. The study of biomarkers for TB is critical for advancing our understanding and management of the disease. Biomarkers, defined as measurable indicators of biological states or conditions, are invaluable for the diagnosis, prognosis and treatment monitoring of TB. Clinical studies have provided critical knowledge on the matter but are also notoriously constrained by economical, ethical and sampling limitations. The use of animal models provides a simpler, more controllable, cost-effective setting with great potential for translation to humans. They also allow the evaluation of biomarkers within the respiratory compartment, when available, which is of particular interest due to the nature of TB pathogenesis. This Review focuses on the current landscape of TB biomarker discovery in several animal models, from invertebrates to large mammals. Here we summarize the basics of host–pathogen immune interaction, describe the main methodological approaches used and highlight the most substantial findings for each animal model studied. Furthermore, we discuss the advantages, challenges and limitations associated with species-specific differences in animal models. We conclude that integrating the data obtained from animal models and human studies is absolutely required to advance the TB field to accelerate the management of this disease., This article is based upon work from COST Action ‘Towards an improvement in diagnostics and treatment strategies for TB control’ (ADVANCE-TB), CA21164, supported by COST (European Cooperation in Science and Technology). This work has been also supported by grants from the Instituto de Salud Carlos III (PI21/00724, PI22/01834 and CP20/00070 to I.L.) integrated in the Plan Nacional I+D+I and co-founded by the ISCIII Subdireccion General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER) and CERCA Programme/Generalitat de Catalunya. F.J.R. is the recipient of ‘la Caixa’ Foundation grant LCF/PR/HR21-00368, MCIN and ‘ESF Investing in your Future’ grants RYC2019-027799-I/AEI/10.13039/501100011033 and PID2022-139754OB-100, and a Robles Chillida Foundation Grant. The Institute of Agrifood Research and Technology (IRTA) is supported by CERCA Programme/Generalitat de Catalunya. J.B.T. was partially supported by the Robert J. Kleberg Jr. and Helen C. Kleberg Foundation. R.S. is recipient of National Institutes of Health (NIH) awards K01OD031898, R21AI170148 and R56AI184089-01A1, and other institutional grants P30 AI-161943 (Texas D-CFAR). J.B.T. and R.S. are part of IN-TRAC P30AI168439. E.J. and E.T. are recipients of grants from the Ministerio de Ciencia, Innovación y Universidades and Agencia Estatal de Investigación (AEI), Spain, cofunded by Fondo Europeo de Desarrollo Regional, FEDER, European Union (PID2021-122331OB-I00 and PID2021-125801OB-100) and AGAUR-Generalitat de Catalunya (2021SGR-0092 and 2021SGR-0145). E.J. is a Serra Hunter Fellow., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The study of immunological markers in tuberculosis across animal models and its translation to human research

  • Díaz-Fernández, Sergio
  • Aleluia, Matilde
  • Saraiva, Margarida
  • Soldevilla, Pablo
  • Torrelles, Jordi B.
  • Sharan, Riti
  • Verreck, Frank A. W.
  • Izzo, Angelo
  • Vidal, Maria
  • Moreira, Ana C.
  • Pérez de Val, Bernat
  • Roca, Francisco Jose
  • Preda, Madalina
  • Torrents, Eduard
  • Julián, Esther
  • Domínguez, José
  • Latorre, Irene
Tuberculosis (TB), a disease caused by Mycobacterium tuberculosis, remains one of the major causes of death from infection worldwide, with over a million associated deaths each year. The study of biomarkers for TB is critical for advancing our understanding and management of the disease. Biomarkers, defined as measurable indicators of biological states or conditions, are invaluable for the diagnosis, prognosis and treatment monitoring of TB. Clinical studies have provided critical knowledge on the matter but are also notoriously constrained by economical, ethical and sampling limitations. The use of animal models provides a simpler, more controllable, cost-effective setting with great potential for translation to humans. They also allow the evaluation of biomarkers within the respiratory compartment, when available, which is of particular interest due to the nature of TB pathogenesis. This Review focuses on the current landscape of TB biomarker discovery in several animal models, from invertebrates to large mammals. Here we summarize the basics of host–pathogen immune interaction, describe the main methodological approaches used and highlight the most substantial findings for each animal model studied. Furthermore, we discuss the advantages, challenges and limitations associated with species-specific differences in animal models. We conclude that integrating the data obtained from animal models and human studies is absolutely required to advance the TB field to accelerate the management of this disease., This article is based upon work from COST Action ‘Towards an improvement in diagnostics and treatment strategies for TB control’ (ADVANCE-TB), CA21164, supported by COST (European Cooperation in Science and Technology). This work has been also supported by grants from the Instituto de Salud Carlos III (PI21/00724, PI22/01834 and CP20/00070 to I.L.) integrated in the Plan Nacional I+D+I and co-founded by the ISCIII Subdireccion General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER) and CERCA Programme/Generalitat de Catalunya. F.J.R. is the recipient of ‘la Caixa’ Foundation grant LCF/PR/HR21-00368, MCIN and ‘ESF Investing in your Future’ grants RYC2019-027799-I/AEI/10.13039/501100011033 and PID2022-139754OB-100, and a Robles Chillida Foundation Grant. The Institute of Agrifood Research and Technology (IRTA) is supported by CERCA Programme/Generalitat de Catalunya. J.B.T. was partially supported by the Robert J. Kleberg Jr. and Helen C. Kleberg Foundation. R.S. is recipient of National Institutes of Health (NIH) awards K01OD031898, R21AI170148 and R56AI184089-01A1, and other institutional grants P30 AI-161943 (Texas D-CFAR). J.B.T. and R.S. are part of IN-TRAC P30AI168439. E.J. and E.T. are recipients of grants from the Ministerio de Ciencia, Innovación y Universidades and Agencia Estatal de Investigación (AEI), Spain, cofunded by Fondo Europeo de Desarrollo Regional, FEDER, European Union (PID2021-122331OB-I00 and PID2021-125801OB-100) and AGAUR-Generalitat de Catalunya (2021SGR-0092 and 2021SGR-0145). E.J. is a Serra Hunter Fellow., info:eu-repo/semantics/publishedVersion